

Trading update: headwinds in China

1st October 2024

In a Trading Update for the six months to 30 September 2024, Eco Animal Health reports reduced demand in China and SE Asia markets for its proprietary Aivlosin[®] porcine treatment, reflecting lower incidence of disease and some customer churn. The Group expects the customary H2 earnings weighting (H2 FY24: 57.5%), whilst Aivlosin[®] continues to gain market share in India and Brazil. However, the combination of demand, foreign exchange and other factors across the full range of EAH's global market presence leads the company at this stage to assess that revenue for the full year should be below market estimates: a consensus indicated of £92.6m and (adj.) EBITDA of £8.2m. Consequently the Group expects FY25 (adj.) EBITDA to be close to FY23 levels (£7.2m).

At this stage we have adjusted our FY25 outlook accordingly. Our FY25 revenue estimate is reduced by 7%, and (adj.) EBITDA by 10%. We remain prudent but will review further as H2 develops.

Aivlosin[®]: reflects global trends

We estimate that Aivlosin[®] typically comprises c.90% of total revenue, with an overall revenue contribution in FY24 of 27.6% from China and Japan and c.40% of (adj.) EBITDA before centralised costs including R&D spend. As a mature product with an established distribution base from the Far East to Europe and the Americas, Aivlosin[®] has remained highly cash-generative; the FY24 cash balance was £22.4m. The Group notes grounds for optimism for H2 performance with improving pork prices in China, strong order books and continued demand in N. America, Brazil and India, combined with regulatory approval for marketing of Aivlosin[®] in Paraguay, a market of 1.4m pigs, 80% farmed intensively.

Well-funded R&D and product commercialisation programme in place

The Group has outlined in detail the range of opportunities presented by its investment in new treatments, notably six underway: ECOVAXXIN[®]MG, ECOVAXXIN[®]MS, ECOVAXXIN[®] PCV-2 Mh, PRRS-V Mab, NE Mab, and anti-parasitics. The area of novel monoclonal solutions in particular has the potential to yield significant results.

Conclusion: transition underway

As EAH has outlined in the past (November 2023 Capital Markets event), the Group has a well-defined and well-funded R&D and product commercialisation programme. By contrast its mainstay product, Aivlosin[®], has a market position which places it at the focus of market demand vagaries, as H1 24 illustrates as the process of transition develops.

Company Data

EPIC	EAH
Price (last close)	96p
52 weeks Hi/Lo	135p/82p
Market cap	£65m
Proforma net debt (cash)	£(22.4)m

Share Price, p



Source: ADVFN

Description

Founded in 1995, ECO Animal Health specialises in the development, registration and distribution of pharmaceutical products for animal health markets worldwide, notably disease, bacterial infection and parasitic prevention for pigs, cattle, sheep and poultry. The Group addresses markets in China and the Far East, SE Asia, North America, Latin America and Europe, and derives c.90% of revenue from its enteric and respiratory antibiotic Aivlosin[®], for the treatment of enteric and respiratory diseases in pigs and poultry.

Forecasts to FY26

Yr to 31 March (£m)	2022	2023	2024	2025E	2026E
Revenue	82.2	85.3	89.4	84.3	85.3
EBITDA (adj.)	5.4	7.2	8.0	7.2	7.9
Pre-Tax Profit (adj.)	3.8	4.8	4.0	4.0	4.3
EPS (rptd. basic)	(1.01)	1.49	1.55	0.96	1.34
EPS (adj. dil. p)	2.47	1.66	2.32	1.08	1.47
Net debt (cash)	(14.3)	(21.7)	(22.4)	(18.3)	(16.8)
EV/EBITDA	7.9x	5.9x	5.3x	5.9x	5.4x
EV/Rev	0.52x	0.50x	0.48x	0.51x	0.50x

Source: Company data, Equity Development estimates. ¹ Net cash is pre-IFRS 16.

Mike Jeremy (Analyst)

0207 065 2690
mike.jeremy@equitydevelopment.co.uk

Hannah Crowe

0207 065 2692
hannah@equitydevelopment.co.uk

Summary financial data

P&L						
Year to 31 March (£m)	FY21	FY22	FY23	FY24	FY25E	FY26E
China & Japan	58.9	28.4	26.4	24.7	21.0	21.2
N America	13.9	16.4	15.2	18.5	18.7	18.9
S & SE Asia	9.1	11.8	16.8	17.4	15.7	15.9
LatAm	14.3	15.8	18.1	19.9	20.1	20.3
Europe	6.6	6.4	6.1	6.5	6.5	6.6
RoW/UK	2.9	3.4	2.8	2.5	2.4	2.4
Revenue	105.6	82.2	85.3	89.4	84.3	85.3
Gross	52.7	35.1	38.4	37.7	33.7	38.0
<i>Margin</i>	49.9%	42.7%	45.0%	42.1%	40.0%	44.5%
COGS	(52.9)	(47.1)	(46.9)	(51.7)	(50.6)	(47.3)
Other income	0.3	0.1	0.4	0.1	0.0	0.0
R&D	(8.1)	(7.6)	(5.9)	(4.2)	(4.0)	(5.0)
Admin	(25.5)	(24.1)	(27.9)	(29.4)	(25.5)	(28.0)
Impairment/Other	0.0	(2.1)	0.0	(0.7)	0.0	0.0
Sum Op-ex	(33.3)	(33.7)	(33.4)	(34.1)	(29.5)	(33.4)
Share-based payments	(0.1)	(0.3)	(0.4)	(0.4)	(0.4)	(0.4)
Forex	2.2	(1.0)	(0.5)	0.6	0.0	0.0
EBIT (rptd.)	19.4	1.4	4.9	3.5	4.3	4.6
EBIT (adj.)	19.6	3.9	5.4	4.6	4.7	5.0
<i>Margin</i>	18.5%	4.7%	6.3%	5.1%	5.5%	5.8%
Amortisation	(0.9)	(1.1)	(1.1)	(1.2)	(1.2)	(1.4)
Amortisation RoU	(0.4)	(0.4)	(0.5)	(0.7)	(0.7)	(0.7)
Depreciation	(0.4)	(0.5)	(0.8)	(1.0)	(0.7)	(0.8)
EBITDA (rptd.)	23.4	2.4	6.8	6.9	6.8	7.5
EBITDA (adj.)	23.5	5.4	7.2	8.0	7.2	7.9
<i>Margin</i>	22.3%	6.6%	8.5%	9.0%	8.5%	9.2%
Financial income	0.1	0.2	0.1	0.2	0.1	0.1
Financial expense	(0.3)	(0.3)	(0.7)	(0.8)	(0.8)	(0.8)
Associate	0.0	0.0	0.0	0.1	0.1	0.1
PBT (rptd.)	19.3	1.4	4.4	3.0	3.6	4.0
PBT (adj.)	19.4	3.8	4.8	4.0	4.0	4.3
Tax	(3.5)	(2.1)	(1.3)	(1.0)	(1.0)	(1.0)
PAT (rptd.)	15.8	(0.7)	3.1	2.0	2.7	2.9
PAT (adj.)	16.0	1.7	3.5	3.1	3.1	3.3
Basic wtd. Av. shares (m)	67.6	67.7	67.7	67.7	67.7	67.7
Diluted wtd. av. shares (m)	67.6	67.7	68.6	69.1	69.1	69.1
EPS rptd. basic (p)	10.86	(1.01)	1.49	1.55	0.96	1.34
EPS rptd. dil. (p)	10.85	(1.01)	1.47	1.52	0.94	1.31
EPS adj. basic (p)	10.94	2.47	1.68	2.37	1.11	1.50
EPS adj. dil. (p)	10.94	2.47	1.66	2.32	1.08	1.47

Source: Company data, Equity Development estimates.

Summary financial data

Cashflow						
Year to 31 March (£m)	FY21	FY22	FY23	FY24	FY25E	FY26E
PBT (rptd.)	19.3	1.4	4.4	3.0	3.6	4.0
Finance (net)	0.2	0.1	0.6	0.6	0.7	0.7
Forex	0.6	(1.0)	(0.5)	0.6	0.0	0.0
Amortisation	0.9	1.1	1.1	1.2	1.2	1.4
Amortisation RoU	0.4	0.4	0.5	0.7	0.7	0.7
Depreciation	0.4	0.5	0.8	1.0	0.7	0.8
Impairment/Other	0.0	2.1	0.0	0.1	0.0	0.0
Associate	(0.0)	(0.0)	(0.0)	(0.1)	(0.1)	(0.1)
Share-based payments	0.1	0.3	0.4	0.4	0.4	0.4
Other	0.0	0.1	(0.0)	0.3	0.0	0.0
Operating Cash Flow	21.9	4.9	7.2	7.7	7.2	7.9
Working capital						
(Increase)/Decrease inventories	(3.7)	(8.6)	7.8	4.7	(6.1)	2.1
(Increase)/Decrease in receivables	(4.0)	7.6	(0.7)	(5.0)	6.8	2.0
Increase/(Decrease) in payables	0.8	(2.9)	2.7	2.5	(1.0)	0.2
Provisions	0.9	1.4	1.4	0.6	0.5	0.5
Movement in working capital	(6.0)	(2.4)	11.2	2.8	0.1	4.8
Cash generated by operations	15.8	2.5	18.4	10.5	7.3	12.7
Interest paid	(0.1)	(0.1)	(0.5)	(0.5)	(0.5)	0.0
Tax (paid)/received	(3.8)	(3.0)	(2.1)	(0.6)	(1.0)	(1.0)
Net cash from operations	12.0	(0.5)	15.9	9.4	5.9	11.7
Investing activities						
PPE	(0.2)	(1.6)	(3.6)	(0.5)	(0.6)	(0.6)
Sale of PPE	0.0	0.0	0.0	1.1	0.0	0.0
Capitalised R&D	(0.9)	(1.3)	(2.4)	(4.1)	(5.0)	(6.3)
Finance	0.1	0.2	0.1	0.2	0.2	0.2
Net cash used in investing	(0.9)	(2.7)	(5.9)	(3.4)	(5.4)	(6.7)
Net OpFCF	11.0	(3.2)	10.0	6.0	0.5	5.0
Financing activities						
Shares issued	0.4	0.1	0.0	0.0	0.0	0.0
Interest on leases	(0.1)	(0.1)	(0.2)	(0.3)	(0.1)	(0.1)
Leases	(0.4)	(0.4)	(0.4)	(0.6)	(0.4)	(0.4)
Dividends	(0.6)	(2.9)	(1.8)	(2.8)	(4.0)	(6.0)
Net cash from financing	(0.7)	(3.3)	(2.4)	(3.7)	(4.5)	(6.5)
Net increase in cash / equivalents	10.4	(6.5)	7.6	2.3	(4.0)	(1.5)
Cash at beginning of year	9.8	19.5	14.3	21.7	22.4	18.3
Forex	(0.7)	1.3	(0.3)	(1.6)	0.0	0.0
Cash at year end	19.5	14.3	21.7	22.4	18.3	16.8

Source: Company data, Equity Development estimates.

Summary financial data

Balance sheet

Year to 31 March (£m)	FY21	FY22	FY23	FY24	FY25E	FY26E
Fixed Assets						
Intangible Assets Net	36.1	34.3	35.6	38.4	42.2	47.0
PPE net	2.2	3.5	6.1	4.8	4.7	4.5
RoU Assets Net	1.4	1.8	4.3	3.7	7.5	13.4
Property Investments	0.3	0.2	0.0	0.0	0.0	0.0
Investments	0.2	0.2	0.3	0.3	0.3	0.3
Deferred Tax	0.3	0.5	0.6	1.4	1.4	1.4
Sum Fixed Assets	40.4	40.5	46.8	48.5	56.1	66.5
Current Assets						
Inventories	20.5	30.1	22.4	17.0	23.1	21.0
Trade receivables	32.5	26.0	26.9	32.2	25.4	23.4
Tax assets, other	4.0	2.7	3.6	3.2	0.0	0.0
Cash, Equivalents	19.5	14.3	21.7	22.4	18.3	16.8
Sum Current Assets	76.5	73.1	74.5	74.7	66.9	61.2
Total Assets	116.9	113.6	121.3	123.3	122.9	127.8
Current Liabilities						
Trade payables	(14.5)	(13.0)	(14.5)	(17.4)	(16.4)	(16.6)
Provisions	(1.8)	(3.9)	(5.2)	(5.9)	(5.9)	(5.9)
Tax, Other	(3.8)	(0.9)	(2.4)	(2.0)	(2.0)	(2.0)
Dividends	(0.1)	(0.1)	(0.1)	(0.1)	0.0	0.0
Sum Current Liabilities	(20.2)	(17.7)	(22.2)	(25.2)	(24.2)	(24.4)
Total Assets less Current Liabilities	96.7	95.9	99.1	98.0	98.7	103.4
Long-term Liabilities						
Deferred tax	(0.2)	0.0	0.0	(1.3)	(1.3)	(1.3)
Leases	(1.2)	(1.5)	(3.6)	(3.4)	(3.4)	(3.4)
Sum Long-term liabilities	(1.4)	(1.5)	(3.6)	(4.7)	(4.7)	(4.7)
Total liabilities	(21.6)	(19.3)	(25.8)	(29.9)	(28.9)	(29.1)
Net Assets	95.3	94.3	95.6	93.4	94.1	98.7
Capital & Reserves						
Share Capital	3.4	3.4	3.4	3.4	3.4	3.4
Share Premium	63.3	63.3	63.3	63.3	61.0	62.7
Reserves	1.9	3.0	2.6	1.6	1.6	1.6
Retained earnings	13.4	12.4	13.9	15.8	18.5	21.4
Non-controlling interests	13.4	12.3	12.3	9.7	9.7	9.7
Equity	95.3	94.3	95.6	93.4	94.1	98.7
Net debt / (cash) IFRS16	(18.3)	(12.8)	(18.1)	(19.0)	(14.9)	(13.4)
Net debt / (cash) excl leases	(19.5)	(14.3)	(21.7)	(22.4)	(18.3)	(16.8)

Source: Company data, Equity Development estimates.



Contacts

Andy Edmond

Direct: 020 7065 2691

Tel: 020 7065 2690

andy@equitydevelopment.co.uk

Hannah Crowe

Direct: 0207 065 2692

Tel: 0207 065 2690

hannah@equitydevelopment.co.uk

Equity Development Limited is regulated by the Financial Conduct Authority

Disclaimer

Equity Development Limited ('ED') is retained to act as financial adviser for its corporate clients, some or all of whom may now or in the future have an interest in the contents of this document. ED produces and distributes research for these corporate clients to persons who are not clients of ED. In the preparation of this report ED has taken professional efforts to ensure that the facts stated herein are clear, fair and not misleading, but makes no guarantee as to the accuracy or completeness of the information or opinions contained herein.

This document has not been approved for the purposes of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom ('FSMA'). Any reader of this research should not act or rely on this document or any of its contents. This report is being provided by ED to provide background information about the subject of the research to relevant persons, as defined by the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

Research produced and distributed by ED on its client companies is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. This document is prepared for clients under UK law. In the UK, companies quoted on AIM are subject to lighter due diligence than shares quoted on the main market and are therefore more likely to carry a higher degree of risk than main market companies.

ED may in the future provide, or may have in the past provided, investment banking services to the subject of this report. ED, its Directors or persons connected may at some time in the future have, or have had in the past, a material investment in the Company. ED, its affiliates, officers, directors and employees, will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

More information is available on our website www.equitydevelopment.co.uk

Equity Development, 2nd Floor, Park House, 16-18 Finsbury Circus, London, EC2M 7EB

Contact: info@equitydevelopment.co.uk | 020 7065 2690